Puma Biotechnology, Inc.

Puma Biotechnology, Inc.

Puma Biotechnology, Inc.

Overview
Date Founded

2010

Headquarters

10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA, 90024, USA

Type of Company

Public

Employees (Worldwide)

318

Industries

Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Contact Data
Trying to get in touch with decision makers at Puma Biotechnology, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Financial Officer

Chief Commercial Officer

Chief Medical & Scientific Officer

Senior Vice President, Finance & Administration & Treasurer

Senior Vice President, Regulatory Affairs, Medical Writing & Project Management

Senior Director, Investor Relations

Senior Director

Senior Director

Senior Director

Board of Directors

Founder at Puma Biotechnology, Inc.

Managing Member at Drayton Investments LLC

Founding Partner at Presidio Partners

Executive Vice President-Commercial at Jazz Pharmaceuticals Plc

Senior Vice President & Chief Medical Officer at Constellation Pharmaceuticals, Inc.

Paths to Puma Biotechnology, Inc.
Potential Connections via
Relationship Science
You
Puma Biotechnology, Inc.
Owners & Shareholders
Details Hidden

OrbiMed Advisors focuses on investments in the global healthcare industry. The firm invests across the spectrum of life sciences companies from early-stage private biotechnology companies to large, publicly-traded pharmaceutical companies. OrbiMed Advisors manages investments across three strategies: mutual funds, hedge funds and private equity funds. The firm is also known to engage in shareholder activist investment strategies.OrbiMed Advisors' hedge fund strategy invests both long and short in the health sciences sector. OrbiMed employs a global investment approach that provides a broad opportunity set and reduced volatility through diversification. They take long positions primarily in small-cap and mid-cap companies with products with the potential for future 'blockbuster' potential.OrbiMed Advisors' mutual funds also invest globally in health sciences companies. Funds under management include the Eaton Vance Worldwide Health Sciences Fund and the Finsbury Worldwide Pharmaceutical Trust. The Eaton Vance Worldwide Health Sciences Fund is a publicly-offered open-end mutual fund that invests globally in biotechnology and pharmaceutical investment opportunities. The Finsbury Worldwide Pharmaceutical Trust is a closed-end UK Investment Trust which also invests globally in biotechnology and pharmaceutical investment opportunities.The firm's private equity activities focus drug discovery, drug development and medical device companies. The firm invests across all stages of company development with particular emphasis on mid- and later-stage private companies. OrbiMed Advisors is generally the lead investor in their portfolio companies and often takes an active role on those companies' boards of directors.

Details Hidden

Consonance Capital Management's (CCM) funds seek to deliver exceptional, uncorrelated risk adjusted returns. CCM seeks to meet this objective by focusing on investment opportunities in the publicly traded stocks of healthcare companies. The firm invests in all sub-sectors of the healthcare sector including healthcare information technology, managed care, pharmaceuticals, specialty pharmaceuticals, commercial stage biotechnology, healthcare facilities and services, medical devices and supplies, diagnostics and consumer-based healthcare companies.CCM believes the public healthcare market lends itself to an active long/short strategy. The firm focuses on creating long and short portfolios driven by the opportunity for absolute return and alpha creation. The funds also invest in other types of securities and may use a variety of investment techniques to generate profit and/or control risk. These may include participating in swaps, buying or selling futures contracts, purchasing and writing options and other derivative contracts, purchasing or selling debt instruments, and trading on margin by borrowing funds and pledging securities as collateral. CCM invests primarily in healthcare companies in the US, and on an opportunistic basis in the rest of the world.^

Details Hidden

JCM offers U.S. equity, global & international equity, fixed income, asset allocation and alternative investment strategies. The firm also offers investment strategies through affiliated investment advisors. The firm seeks to add value versus benchmarks by actively pursuing alpha generation through proprietary fundamental research. They look for companies with misunderstood fundamentals and price dislocations, as well as rapidly growing companies for some equity strategies. For their equity strategies, JCM favors businesses with sustainable above-average earnings growth potential, outstanding free-cash flow generation, recurring revenue and strong profit margins and return on invested capital. The firm's fixed-income research focuses on businesses that have strong or improving balance sheets, improving free-cash flow generation and recurring revenue. They use a proprietary fixed-income risk management tool named Quantum which allows them to view relative value, risk and returns at the portfolio level, individual credit level and across the investable credit universe globally.

Recent Transactions
Details Hidden

Puma Biotechnology, Inc. issued Common Stock

Details Hidden

Puma Biotechnology, Inc. issued Common Stock

Details Hidden

Puma Biotechnology, Inc. issued Common Stock

Transaction Advisors
Manager

Advised onPuma Biotechnology, Inc. issued Common Stock

Manager

Advised onPuma Biotechnology, Inc. issued Common Stock

Legal Advisor

Advised onPuma Biotechnology, Inc. issued Common Stock

Legal Advisor

Advised onPuma Biotechnology, Inc. issued Common Stock

Underwriter

Advised onPuma Biotechnology, Inc. issued Common Stock

Managing Director

Advised onPuma Biotechnology, Inc. issued Common Stock

Clients

CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China.

Medison Pharma Ltd. markets and distributes medical, pharmaceutical, and diagnostics devices and products. It offers services like registration, reimbursement, nursing, distribution, and marketing. The firm is a marketing group, which represents niche healthcare products from companies such as Biogen Idec, Amgen, Shire and Ipsen. The company was founded by Meir Jakobsohn in 1996 and is headquartered in Petach Tikva, Israel.

Key Stats and Financials As of 2017
Market Capitalization
$869M
Total Enterprise Value
$3.64B
Earnings Per Share
$-7.85
Revenue
$27.7M
TEVNet Income
-12.47x
Debt TEV
0.01x
Net Profit
$-292M
Total Debt
$48.5M
EBITDA
$-290M
Total Equity
$53.3M
EBITDAMargin
-1,045.98%
Enterprise Value Sales
131.52x
Investors
Details Hidden

Wellington Management Co. LLP (Private Equity) focuses in companies located in US. The firm invests in consumer discretionary, technology, financial services, biotech, and health care. They provide capital for growth and later stage capital requirement.

Details Hidden

Fidelity Management & Research Co.'s (FMR) investment approach is based on a rigorous, fundamental, bottom-up stock selection process. The firm seeks to identify and invest in the stocks of companies with the potential for long-term capital appreciation or companies with hidden or unrealized value.FMR uses a wide variety of investment strategies in managing client assets, including, but not limited to, investments in: stocks and other equity securities; stocks with growth or value characteristics; bonds and other debt securities and repurchase agreements for those securities; and real estate related investments. The firm may participate in short sales, margin transactions, and option writing, including covered options, uncovered options or spreading strategies. FMR invests in US and non-US issuers, including issuers in emerging or frontier markets. They invest in companies with small, medium and large market capitalizations. Investments are allocated across different asset classes, market sectors, maturities, countries, and regions. Investments may be made in the securities of companies engaged in particular industries or market sectors and in a combination of underlying Fidelity funds.Margin may be required in connection with certain client futures and options transactions or in connection with short sales. FMR does not engage in the purchase of securities on margin, except in connection with the clearance and settlement of securities transactions.FMR may engage in swap transactions and swaptions, including interest rate, total return and credit default; written covered call options; and futures transactions, currency spot and forward trading and other currency related derivatives. In addition, FMR may engage in securities lending to parties such as broker-dealers or other institutions.

Details Hidden

OrbiMed focuses exclusively on global investments across the entire spectrum of private and publicly-traded life sciences companies. They seek to invest in the most promising investment opportunities regardless of a company's stage of development. The firm invests at all stages of development from private start-ups and university spinouts to the largest global pharmaceutical companies. OrbiMed focuses on companies involved in drug development, drug discovery and medical devices, with particular emphasis on mid-stage private companies. Investments typically range from $5 million to $40 million. OrbiMed is generally a lead investor and takes an active role on their portfolio companies' boards of directors

Suppliers
Pfizer, Inc. Medical Support Services | New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

CaligorRx, Inc. Medical Products & Equipment | Secaucus, NJ

Caligor RX, Inc. provides clinical trial supply and logistics services. It manages the regulatory, logistics, and supply chain challenges of sourcing, storing, and distributing investigational drugs for comparator clinical trials and unlicensed medicines for expanded access programs. The firm serves pharmaceutical and biotechnology companies. The company is headquartered in Secaucus, NJ.

Competitors
Seattle Genetics, Inc. Pharmaceuticals - Bothell, WA

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Novartis AG Pharmaceuticals - Basel, BS

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Roche Holding AG Pharmaceuticals - Basel, BS

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy